| Bioactivity | GK563 is a selective Ca2+-independent phospholipase A2 (GVIA iPLA2) inhibitor with an IC50 value of 1 nM. GK563 is 22000 times more active against GVIA iPLA2 than GIVA cPLA2. GK563 reduces β-cell apoptosis induced by proinflammatory cytokines, raising the possibility that it can be beneficial in countering autoimmune diseases, such as type 1 diabetes[1]. |
| Invitro | GK563 (0.091 M) inhibits the activity of 100% GVIA iPLA2, 88% GVIA cPLA2 and 25% GV sPLA2[1].GK563 (0-0.1 μM) inhibits GVIA iPLA2 with a XI(50) value of 0.0000021 and inhibits GVIA cPLA2 with an IC50 value of 22 μM[1].GK563 (0-0.1 μM) shows a better inhibitory effect than fluoroketone FKGK18 to GVIA iPLA2 with an IC50 value of 1 nM[1].GK563 (0-0.1 μM; 16 h) reduces β-cell apoptosis induced by proinflammatory cytokines[1]. Apoptosis Analysis[1] Cell Line: |
| Name | GK563 |
| CAS | 2351820-19-2 |
| Formula | C16H22O2 |
| Molar Mass | 246.34 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |